Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.53 |
| ▸ | KHK | P50053 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30990743 | 0.94 | DDB1 (0.52) | DDB1CRBNKHKDRD2BRD4 | |
| SCHEMBL31160727 | 0.89 | DDB1 (0.49) | DDB1CRBNKHKDRD2BRD4 | |
| SCHEMBL27168231 | 0.88 | DDB1 (0.62) | DDB1CRBNDRD2KCNH2 | |
| SCHEMBL27167653 | 0.88 | DDB1 (0.62) | DDB1CRBNDRD2KCNH2 | |
| SCHEMBL29976664 | 0.88 | DDB1 (0.62) | DDB1CRBNDRD2KCNH2 | |
| SCHEMBL31160800 | 0.87 | DDB1 (0.49) | DDB1CRBNKHKDRD2BRD4 | |
| SCHEMBL29976687 | 0.86 | DDB1 (0.63) | DDB1CRBNKHKKCNH2 | |
| SCHEMBL27167811 | 0.86 | DDB1 (0.63) | DDB1CRBNKHKKCNH2 | |
| SCHEMBL27167809 | 0.86 | DDB1 (0.63) | DDB1CRBNKHKKCNH2 | |
| SCHEMBL27167868 | 0.86 | DDB1 (0.63) | DDB1CRBNKHKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182555-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | DDB1 308/4885CRBN 429/4885KHK 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.